ESMO: European Society for Medical Oncology

  1. Evidence for efficacy is based on the results from the HORIZON study

  2. Evidence for efficacy is based on the results from the CHECKMATE-649 study

  3. It includes age and lung metastases as additional adverse prognostic factors and uses a single cut-off of LDH at 2.5× ULN 

  4. A new analysis from US show that response to genome-targeted therapy increased from 2.73% in 2006 to 7.04% in 2020

  5. Evidence for efficacy and safety is based on the results from the TROPHY study